title: Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
abstract: Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i.v. every 3 weeks) + 5-fluorouracil (600 mg/mq i.v. bolus/weekly) and 5-fluorouracil alone (same schedule). In the 54 evaluable patients, no CR was observed. PR rate was 19.2% for the combination, and 14.5% for the monochemotherapy. Also the overall median survival time was similar for the two arms (10 and 13 months, respectively). Toxicity was acceptable, with more side-effects in the combination arm. Both treatments are of limited activity in advanced colorectal cancer and no advantage comes out from the use of this polychemotherapy.
authors.affiliation: Medical Oncology Department, S. Carlo Borromeo Hospital, Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Labianca
authors.forename: G
authors.initials: G
authors.lastname: Pancera
authors.forename: B
authors.initials: B
authors.lastname: Cesana
authors.forename: M
authors.initials: M
authors.lastname: Clerici
authors.forename: F
authors.initials: F
authors.lastname: Montinari
authors.forename: G
authors.initials: G
authors.lastname: Luporini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
chemical_list: D002945:Cisplatin; D005472:Fluorouracil